Pre-clinical models consistently indicate that early interventions, including castration and genetic knockout of AR, inhibit cancer onset and burden3,9,35, whereas later stage interventions exhibit significantly less anti-cancer activity2–4,14. This evidence concerns the gene AR and cancer.